A Phase 2 Safety Study of Accelerated Elotuzumab Infusion, Over Less Than 1 H, in Combination With Lenalidomide and Dexamethasone, in Patients With Multiple Myeloma

American Journal of Hematology - United States
doi 10.1002/ajh.24687

Related search